trending Market Intelligence /marketintelligence/en/news-insights/trending/v4fN3DH9rDVjtJ4vrCHl-A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aradigm respiratory disease drug not likely to get EMA backing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aradigm respiratory disease drug not likely to get EMA backing

Aradigm Corp. said its respiratory disease drug Linhaliq is not likely to get the backing of the European Medicines Agency in November.

The Hayward, Calif.-based company previously filed a centralized marketing authorization application for Linhaliq for treating non-cystic fibrosis bronchiectasis patients with chronic lung infections with P. aeruginosa. Non‐cystic fibrosis bronchiectasis is a condition in which the bronchial tubes in the lungs are scarred and widened.

Aradigm said it received feedback, following an oral explanation with the EU agency, that the drug is likely to receive a negative opinion from the EMA's Committee for Medicinal Products for Human Use.

Amsterdam-based EMA makes recommendations to the European Commission, which ultimately decides whether to approve or reject manufacturers' applications for marketing approval in the European Union.

Meanwhile, the company is also seeking approval in the U.S. for the drug, known in the U.S. as Apulmiq, for the same indication. In January, the company completed an independent third-party evaluation of two phase 3 studies for the therapy as requested by the U.S. Food and Drug Administration.

In February, Aradigm filed for bankruptcy protection and said it intends to begin selling substantially all of its assets.